Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (November 2022)
33 slides from Ibio's investor presentation, Nov 3, 2022
Slide 1: November 2022 iBio, Inc.
November 2022 © iBio, Inc., All Right Reserved
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue,
Slide 3: High failure rate of traditional drug discovery drives high cost of new therapies
The high failure rate of targets derived from traditional drug discovery methods contribute to the high cost of developing new therapies Industry Benchmarks to Reach IND1 Failure Rate >99% Time >3 Years Cost >$20-60M2 1 https:// www.researchgate.net/publication/265288848_The_Global_Biomedical_Indust
Slide 4: Antibody engineering is hard: programs fail to selectively bind disease-causing cells
Antibody engineering is hard: drug programs often fail due to the inability of molecules to selectively bind to disease-causing cells vs. healthy ones Antibodies are built from stretches of amino acids, which are the words and sentences that make up the natural language of biology. We are using AI t
Slide 5: AI-powered RubrYc Discovery Engine against hard-to-drug targets
hard - to - drug targets Leveraging AI-powered discovery engine to develop precision antibody candidates against AI-powered RubrYc® Discovery Engine Pipeline against hard-to-drug targets Growing pipeline with immuno-oncology focus Execution Treg depleting anti-CD25 PD-1 agonist Tumor-selective EGFRv
Slide 6: Our AI-driven RubrYc Discovery Engine tech stack
Our AI-driven RubrYc® Discovery Engine tech stack Epitope 1 Engineering Engine • Proprietary epitope steering for challenging targets and MoAs • AI-engineered epitope preserves target structure Antibody Library Antibody 3 Optimizer • Fully human sequences • Uses clinically validated antibody framewo
Slide 7: The RubrYc Discovery Engine in action
RubrYc AI - generated naïve antibody Epitope Engineering Engineered Optimizer The RubrYc Discovery Engine in action AI-powered precision targeting of conformational & sub-dominant epitopes Epitope-specific antigens built to efficiently & selectively discover antibodies Epitope-specific mAbs processe
Slide 8: Therapeutics pipeline growth driven by cancer immunotherapies
Therapeutics pipeline growth and maturation driven primarily by cancer immunotherapies developed with the RubrYc Discovery Engine Fibrosis Systemic Scleroderma Idiopathic Pulmonary IBIO-100 Fibrotic Diseases Autoimmune Disease PD-1 Autoimmune Solid Tumors Solid Tumors Immuno-Oncology Immuno-Oncology
Slide 9: AI platform powers a focused, capital efficient business plan
Our AI platform powers a focused, capital efficient business plan • Advancing a select few “fast followers” • Licensing and asset sales for other molecules • Partner existing molecules or discovery projects against new targets • Potential for upfront, milestone payments and/or royalties Proprietary
Slide 10: IBIO-101 IL-2 sparing anti-CD25
IBIO-101 IL-2 sparing anti-CD25 10
Slide 11: IBIO-101 for regulatory T-cell (Treg) depletion
IBIO-101 for regulatory T-cell (Treg) depletion *Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases 11 IL-2 sparing anti-CD25 antibodies enables depletion of Tregs withou
Slide 12: IBIO-101 reduces tumor growth by selectively depleting Tregs
IBIO-101 reduces tumor growth by selectively depleting immuno-suppressive Tregs without affecting cancer killing Teffs 1st gen CD25 mAbs depleted immuno- suppressive Treg and immuno-stimulatory Teff Limited efficacy 2nd gen RTX-003 selectively targets Tregs without blocking IL-2 signaling to Teffs S
Slide 13: IBIO-101 selectively depletes Tregs
IBIO-101 selectively depletes Tregs iBio-101 potently binds recombinant CD25 while preserving IL-2 signaling which leads to Treg depletion while sparing Teffs RG6292 Roche’s monoclonal antibody that targets CD25 (IL - 2R .. IBIO - 101 is Data on file
Slide 14: IBIO-101 increases Teff/Treg ratio, inhibiting tumor growth
* Significant vs hIgG1 Isotype - Data on file. IBIO-101 increases in Teff/Treg ratio, inhibiting tumor growth Potently increases T-eff/T-reg ratio1 Tumor growth inhibition correlates with T-eff/T-reg ratio * Significant vs Negative Control
Slide 15: IBIO-101 with checkpoint inhibitor shows greater efficacy
IBIO-101 in combination with a checkpoint inhibitor shows greater efficacy IBIO-101 + PD-1 Checkpoint Inhibitor Enhances Tumor Suppression *hCD25 animal model - Data on file. * Significant vs Negative Control # Significant vs Anti-PD-1
Slide 16: Anti-EGFRvIII
Anti-EGFRvIII High ADCC mAb against tumor-specific EGFRvIII cells 16
Slide 17: Anti-EGFRvIII program for glioblastoma and other cancers
tion to acquire Cullinan Oncology’s subsidiary, Cu linan Pearl, which has worldw EGFRvIII for glioblastoma and other cancers PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Seagen / LAVA Therapeutics (Sep. 2022): $50M upfront, $650M in milestones **Taiho / Cullinan Oncology (May
Slide 18: Anti-EGFRvIII mAbs selectively kill EGFRvIII-positive tumor cells
iBio’s Anti-EGFRvIII mAbs selectively kill EGFRvIII-positive tumor cells and not EGFR1-expressing cells in healthy tissues iBio mAb binding specifically to EGFRvIII Tumor Size Reduction Tumor Size Reduction Non-EGFRvIII specific mAb binds to EGFR1 in skin iBio mAb binding specifically to EGFRvIII iB
Slide 19: EGFRvIII-selective mAbs kill tumor cells without affecting healthy cells
but not binding wild - type EGFR1 and thus not affecting healthy cells Data on file iBio’s EGFRvIII-selective mAbs kill tumor cells without affecting healthy cells iBio EGFRvIII mAbs bind recombinant EGFRvIII which leads to tumor cell killing
Slide 20: Anti-CCR8
Anti-CCR8 Highly ADCC anti-CCR8 for the depletion of T-regulatory cells 20
Slide 21: CCR8 for tumor-infiltrating Treg depletion
CCR8 for tumor-infiltrating Treg depletion PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Fibrogen / HiFiBio (Jun. & Dec. 2021): $25M option fee, $35M option exercise, $1.1B milestones **Gilead / Jounce (Sep. 2020): $85M upfront, $35M equity investment, $685 clinical, regulatory
Slide 22: CCR8+ Treg cells are tumor infiltrating and highly immunosuppressive
CCR8+ Treg cells are tumor infiltrating and highly immunosuppressive Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity - 520; Kidani CCR8 & CCR4 non specific antibody iBio CCR8 specific antibody Intratumor cytotoxic T - cell activation & tumor death CCR4+ cells spared System
Slide 23: CCR8 antibodies have high-specificity binding and ADCC cell killing
CCR8 antibodies have high-specificity binding and ADCC cell killing High Specificity CCR8 Cell Binding High Specificity & Potent Cell Killing (no ADCC enhanced Fc engineering) HIGHER CELL BINDING ANTIBODY CONCENTRATION (NM) Data on file EC50 = 0.098 nM Benchmark EC50 = 0.120 nM Strong binding to CCR
Slide 24: PD-1 agonist
PD-1 agonist Supports restoration of homeostasis for inflammatory diseases 24
Slide 25: PD-1 Agonist for inflammatory disorders
PD-1 Agonist for treatment of inflammatory disorders while preserving low inflammation state in healthy tissue PRECLINICAL TESTING IND CLINICAL TESTING CLINICAL PROOF OF CONCEPT *Gilead / Mirobio (Aug. 2022): Acquired for $405M **Merck / Pandion (Feb. 2021): Acquired for $1.85B *Gilead / Mirobo: Mir
Slide 26: Antagonizing PD-1 with PD-L1 blocking worsens autoimmunity
Antagonizing PD-1 with PD-L1 blocking worsens autoimmunity and systemic inflammation Autoimmunity Increased & systemic inflammation Strong inhibition TCR MHC PD - 1 PD - L1 presenting T-cell T - cell PD - 1 Weak T-cell inhibition T-cell Worsened
Slide 27: Agonizing PD-1 without blocking PD-L1 restores T-cell suppression
Agonizing PD-1 without blocking PD-L1 restores activated T-cell suppression Autoimmunity Healthy Tissue Low-inflammation preserved Diseased Tissue Reduced inflammation Strong inhibition TCR MHC Strong inhibition PD - 1 PD - L1 presenting T - cell PD - 1 Weak T-cell inhibition Strong inhibition Impro
Slide 28: In vitro PD-1 agonism equals or surpasses benchmarks
In vitro PD-1 agonism equals or surpasses benchmarks and PD-L1 Ab ID EC50 (nM) SD-671823 0.88 SD-300670 0.31 SD-030629 0.36 SD-136366 0.28 SD-759028 0.52 SD-313018 (bispecific) 0.30 AnaptysBio APE12095 17.4 BMS/Celgene PD1AB6 0.76 IgG1 isotype control inactive Data on file SD - 1018 (bispecific SD -
Slide 29: Primary T-cell suppression equals or surpasses benchmarks
Primary T-cell suppression equals or surpasses benchmarks and PD-L1 200 Mean of 6 donors IL-2 at 24 hrs. 300 Mean of 6 donors CD69 at 72 hrs. 200 100 Anti-HEL IgG1 Isotype Control 100 Anti-HEL IgG1 Isotype Control 0 0 Data on file % IL - 2 Release CD69 MFI iBio Molecules Benchmark Molecules Natural
Slide 30: In summary
iBto In summary
Slide 31: Strong and growing IP estate provides exclusivity
Strong and growing IP estate provides exclusivity for iBio’s pipeline 107 Issued Patents (25 U.S.) 35 Active Applications (12 U.S.) Patent protection includes: • Intellectual property (IP) around iBio’s biopharmaceutical candidates • IP related to the RubrYc® Discovery Engine (including Notice of Al
Slide 32: Our leadership team brings drug development & bioprocessing experience
Our leadership team brings drug development & bioprocessing experience Martin Brenner, DVM, Ph.D. CSO Robert Lutz, MBA CFBO Marc Banjak GC Lisa Middlebrook CHRO Tom Isett CEO
Slide 33: iBio: Summary
iBio: Summary Pipeline of difficult to find biologics • Pipeline of 10 preclinical primarily immuno- oncology (I/O) biologics • Targets have been of interest to major I/O companies • Lead asset is a next- generation anti-CD25 (fast follower to Roche’s RG6292) • Expected to file IND no later than H1